EC OKs Amgen's Avastin biosimilar

Jan. 18, 2018 4:26 PM ETAmgen Inc. (AMGN)By: Douglas W. House, SA News Editor8 Comments
  • As expected, the European Commission (EC) approves Amgen (NASDAQ:AMGN) and development partner Allergan's (AGN) MVASI, a biosimilar of Roche's (OTCQX:RHHBY) Avastin. The FDA approved it in September 2017.
  • Two months ago, the advisory group CHMP adopted a positive opinion backing approval.
  • The companies are collaborating on the development and commercialization of four oncology biosimilars. Amgen has 10 in its portfolio.
  • Previously: European advisory group backs Amgen's Avastin biosimilar ABP 215 (Nov. 10, 2017)

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.